ERBB2 and neoplasm: The assessment of tumor tissue for the expression of programmed death ligand-1 (PD-L1), human epidermal growth factor receptor-2 (HER2) and DNA mismatch repair (MMR) enzymes informs the recommendation for complementing systemic treatment with PD-1-directed immune checkpoint inhibition or HER-2-directed targeted treatment.